Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
Antiobesity drugs that target peripheral metabolism may avoid some of the problems that have been encountered with centrally acting anorectic drugs. Moreover, if they cause weight loss by increasing fat oxidation, they not only address a cause of obesity but also should promote loss of fat rather than lean tissue and improve insulin sensitivity. Weight loss may be slow but more sustained than with anorectic drugs, and thermogenesis may be insufficient to cause any discomfort. Some thermogenic approaches are the activation of adrenergic, thyroid hormone or growth hormone receptors and the inhibition of glucocorticoid receptors; the modulation of transcription factors [e.g. peroxisome proliferator-activated receptor delta (PPARdelta) activators] or enzymes [e.g. glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors] that promote mitochondrial biogenesis, and the modulation of transcription factors (PPAR alpha activators) or enzymes (AMP-activated protein kinase) that promote fatty acid oxidation. More surprisingly, studies on genetically modified animals and with enzyme inhibitors suggest that inhibitors of fatty acid synthesis [e.g. ATP citrate lyase, fatty acid synthase, acetyl-CoA carboxylase (ACC)], fatty acid interconversion [stearoyl-CoA desaturase (SCD)] and triglyceride synthesis (e.g. acyl-CoA : diacylglycerol acyltransferase) may all be thermogenic. Some targets have been validated only by deleting genes in the whole animal. In these cases, it is possible that deletion of the protein in the brain is responsible for the effect on adiposity, and therefore a centrally penetrant drug would be required. Moreover, whilst a genetically modified mouse may display resistance to obesity in response to a high fat diet, it requires a tool compound to demonstrate that a drug might actually cause weight loss. Even then, it is possible that differences between rodents and humans, such as the greater thermogenic capacity of rodents, may give a misleading impression of the potential of a drug.
Clapham
J C
JC
Department of Molecular Pharmacology, AstraZeneca R & D Mölndal, Mölndal, Sweden.
Arch
J R S
JR
D055372:AMP-Activated Protein Kinases; D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005227:Fatty Acids / Q000096:biosynthesis; D006727:Hormone Antagonists / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects; D008928:Mitochondria / Q000502:physiology; D009097:Multienzyme Complexes / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy* / Q000209:etiology; D017346:Protein Serine-Threonine Kinases / Q000627:therapeutic use; D012377:Rodentia; D013564:Sympathetic Nervous System / Q000187:drug effects; D022722:Thermogenesis / Q000502:physiology; D014280:Triglycerides / Q000096:biosynthesis; D014475:Uncoupling Agents / Q000627:therapeutic use
D019440:Anti-Obesity Agents; D005227:Fatty Acids; D006727:Hormone Antagonists; D006728:Hormones; D009097:Multienzyme Complexes; D014280:Triglycerides; D014475:Uncoupling Agents; D017346:Protein Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases